Interpretation of Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022 (Ⅵ) : anticancer drug therapy for patients on dialysis and after kidney transplantation
10.3760/cma.j.cn114015-20240724-00628
- VernacularTitle:《抗肿瘤药物治疗期间肾损伤管理临床实践指南（2022）》解读（六）：透析和肾移植术后患者的抗肿瘤药物治疗
- Author:
Simiao ZHAO
1
;
Xiaoyan SHENG
;
Jianghua SHEN
;
Ying ZHOU
Author Information
1. 北京大学第一医院药剂科，北京 100034
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents;
Renal insufficiency;
Dialysis;
Kidney transplantation;
Guideline;
Interpretation
- From:
Adverse Drug Reactions Journal
2024;26(10):577-583
- CountryChina
- Language:Chinese
-
Abstract:
With the spread of hemodialysis therapy and the continuous breakthrough of kidney transplantation technology, the survival period of patients with end-stage renal disease is prolonged, and malignant tumor has become one of the main causes for hospitalization and death of patients on hemodialysis and undergoing kidney transplantation. Due to the particularity of pharmacokinetics in patients on dialysis and the long-term maintenance immunosuppressive therapy in kidney transplant patients, many aspects need to be considered and balanced in these patients when they need anti-tumor drug treatments. The Japanese Society of Nephrology, Japan Society of Clinical Oncology, Japanese Society of Medical Oncology, and Japanese Society of Nephrology and Pharmacotherapy have jointly formulated Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022, and systematically answers many clinical questions about anticancer drug therapy in patients on hemodialysis and underwent kidney transplantation in the second chapter. This article interprets this part to provide references for the anti-tumor drug treatments of patients on dialysis and after kidney transplantation in China.
